Next-generation nanomedicine for acute ischemic stroke

治疗急性缺血性中风的下一代纳米药物

基本信息

  • 批准号:
    10603229
  • 负责人:
  • 金额:
    $ 30.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-20 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT / PROJECT SUMMARY Acute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary injury caused by ischemia-reperfusion injury. To solve this problem, many neuroprotective drugs were trialed, but all failed, largely due to poor drug delivery to at-risk brain. Therefore, a new technology is needed to deliver neuroprotective drugs to re- and under-perfused brain. To meet this challenge, University of Pennsylvania spin-out NanoMuse will build on our two recent breakthroughs: First, we discovered that nano-scale drug carriers (nanocarriers) that bind to the endothelial marker VCAM can concentrate drugs in the brain >30x higher than if delivered without a nanocarrier, and >6x better than the best prior nanocarrier. In the gold-standard stroke model of transient middle cerebral artery occlusion (tMCAO) in mice, VCAM-nanocarriers loaded with the corticosteroid dexamethasone improved mortality and reduced infarct volume 32% (more than the 25% average of drugs that progressed to clinical studies). Second, we found that prior nanocarriers suffered from activation of the complement protein cascade, which limits nanocarrier uptake in the brain and produces an anaphylaxis-like reaction that drops the blood pressure (very dangerous in stroke). Therefore, we conjugated a human complement-inhibitor (Factor I) to the nanocarriers, and completely eliminated these problems. Now we will combine and extend these two innovations to develop our product, a nanocarrier that massively concentrates neuroprotective drugs in at-risk brain, initially in ischemic stroke patients after reperfusion. In Aim 1, we will optimize the nanocarriers (e.g., switching the VCAM-targeting moiety to an Fab antibody fragment) to minimize complement activation and phagocytosis of the particles, using mouse and human serum and leukocytes. In Aim 2, we will use the optimized nanocarriers to test 3 drugs for efficacy in the tMCAO mouse model: dexamethasone (already proven effective with our un-optimized nanocarrier), or mRNAs encoding two anti-inflammatory proteins (which we already showed were effective in other mouse models). We will measure infarct volume, behavioral outcomes, side effects, drug distribution, and mRNA-encoded protein production compared to untargeted or drug-free nanocarriers. The best mono-therapy and a combination therapy will be validated in tMCAO with advanced age. Our deliverable will be a nanocarrier to concentrates one or two anti-inflammatory drugs at the BBB in order to ameliorate infarct volume by > 25%. Our team is poised to do this, with clinicians who take care of stroke, nanotechnologists, business advisors with years of experience in neuro-critical care products, and a supportive university. Together, we will help usher in stroke’s next revolution.
摘要/项目总结 急性缺血性中风即将迎来一场革命。随着机械血栓切除术在 最严重的血栓都能被移除虽然血栓切除术改善了结局,但大多数治疗 患者仍然有严重的缺陷,这在很大程度上是由于缺血-再灌注损伤引起的继发性损伤。 为了解决这个问题,许多神经保护药物进行了试验,但都失败了,主要是由于药物输送不良 危险的大脑。因此,需要一种新的技术来提供神经保护药物, 脑灌注不足。为了迎接这一挑战,宾夕法尼亚大学的NanoMuse将建立在我们的基础上, 最近的两个突破:首先,我们发现纳米尺度的药物载体(纳米载体),结合到 内皮标记物VCAM可以使药物在大脑中的浓度比在没有内皮标记物的情况下递送高30倍。 纳米载体,并且比最好的现有纳米载体好> 6倍。在金标准中风模型的瞬态 在小鼠大脑中动脉闭塞(tMCAO)中,负载皮质类固醇的VCAM-纳米载体 地塞米松改善了死亡率,并使梗死体积减少了32%(超过了 进行临床研究)。第二,我们发现,先前的纳米载体遭受激活的纳米颗粒。 补体蛋白级联,其限制脑中的纳米载体摄取并产生过敏样 降低血压的反应(在中风中非常危险)。因此,我们结合了一个人类 补体抑制剂(因子I)的纳米载体,并完全消除了这些问题。现在我们将 联合收割机并扩展这两项创新,开发我们的产品,一种纳米载体, 神经保护药物在危险大脑中的应用,最初是在缺血性中风患者再灌注后。在目标1中,我们 优化纳米载体(例如,将VCAM靶向部分转换为Fab抗体片段)以最小化 使用小鼠和人血清和白细胞,观察颗粒的补体激活和吞噬作用。在 目的2,我们将使用优化的纳米载体来测试3种药物在tMCAO小鼠模型中的功效: 地塞米松(已经用我们未优化的纳米载体证明有效),或编码两种 抗炎蛋白(我们已经证明在其他小鼠模型中有效)。我们将测量 梗死体积、行为结果、副作用、药物分布和mRNA编码蛋白质产生 与非靶向或无药物的纳米载体相比。最好的单药治疗和联合治疗将是 在高龄患者的tMCAO中得到验证。我们的成果将是一种纳米载体, 在BBB处使用抗炎药,以将梗塞体积改善> 25%。我们的团队准备好了 这一点,与临床医生谁照顾中风,纳米技术专家,商业顾问与多年的经验, 神经重症监护产品和支持性大学。我们将一起帮助迎接中风的下一个 革命

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jacob Brenner其他文献

Jacob Brenner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jacob Brenner', 18)}}的其他基金

miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis
miRNA-纳米技术作为淋巴管平滑肌瘤病的新型再生疗法
  • 批准号:
    10761353
  • 财政年份:
    2023
  • 资助金额:
    $ 30.05万
  • 项目类别:
The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone
防止阿片类药物过量死亡的 DOVE 装置:可感应过量并自动注射纳洛酮的臂带
  • 批准号:
    10485568
  • 财政年份:
    2023
  • 资助金额:
    $ 30.05万
  • 项目类别:
mRNA-LNPs for ARDS
ARDS 的 mRNA-LNP
  • 批准号:
    10659792
  • 财政年份:
    2023
  • 资助金额:
    $ 30.05万
  • 项目类别:
Controlling complement to unleash nanomedicine for acute critical illnesses
控制补体释放纳米药物治疗急性危重疾病
  • 批准号:
    10557895
  • 财政年份:
    2022
  • 资助金额:
    $ 30.05万
  • 项目类别:
Controlling complement to unleash nanomedicine for acute critical illnesses
控制补体释放纳米药物治疗急性危重疾病
  • 批准号:
    10340537
  • 财政年份:
    2022
  • 资助金额:
    $ 30.05万
  • 项目类别:
RBC-mediated mopping of cytokines for the treatment of pneumonia
红细胞介导的细胞因子清除治疗肺炎
  • 批准号:
    10495259
  • 财政年份:
    2021
  • 资助金额:
    $ 30.05万
  • 项目类别:
RBC-mediated mopping of cytokines for the treatment of pneumonia
红细胞介导的细胞因子清除治疗肺炎
  • 批准号:
    10353073
  • 财政年份:
    2021
  • 资助金额:
    $ 30.05万
  • 项目类别:
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries
ARDS 纳米医学:将药物靶向肺泡毛细血管内多种细胞类型的新范例
  • 批准号:
    10678910
  • 财政年份:
    2020
  • 资助金额:
    $ 30.05万
  • 项目类别:
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries
ARDS 纳米医学:将药物靶向肺泡毛细血管内多种细胞类型的新范例
  • 批准号:
    10030992
  • 财政年份:
    2020
  • 资助金额:
    $ 30.05万
  • 项目类别:
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillaries
ARDS 纳米医学:将药物靶向肺泡毛细血管内多种细胞类型的新范例
  • 批准号:
    10466854
  • 财政年份:
    2020
  • 资助金额:
    $ 30.05万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 30.05万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了